De Brauw Blackstone Westbroek has advised Amgen Inc. on the USD 1.55 billion acquisition of Dezima Pharma.

Dezima is a privately held, Netherlands-based biotechnology company, focused on developing innovative treatments for dyslipidaemia. De Brauw acted as local counsel to Amgen.

Team

Mark Rebergen (lead partner), Jasper Zents, Kees Kraaiveld, Okke Suurenbroek, Ingrid Mensing, Daniel van Gerven